investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Role of PGDH in leukemia pathogenesis
Michael L Cleary
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
No posts
Related projects
Paul B. Jacobsen
Internet-Assisted Cognitive Behavior Intervention for Targeted Therapy Fatigue
Leukaemia
Michael Ryan Corces-Zimmerman
Functional significance of Pre-Leukemic HSC in Human Acute Myeloid Leukemia
Leukaemia
Derek B. Sant'Angelo
Control of cytokine production by human NK cells
Leukaemia
Bruce R Blazar
Cytotoxic-T-Lymphocyte (CTL) Therapy of Acute Myeloid Leukemia (AML)
Leukaemia
Pathology
Hematology and hematologic malignancies
Alex Kentsis
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
Leukaemia
James You
Role of MicroRNAs in the Tumorigenesis of T-ALL
Leukaemia
Pathology
Hematology and hematologic malignancies
Peter Aplan
Collaborative Pathways that Lead to Leukemia – Rockville
Leukaemia
Pathology
Hematology and hematologic malignancies
Joseph H Antin
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT
Leukaemia
M. James You
CHARACTERIZATION AND TARGETED THERAPY OF T-ALL DEFICIENT FOR PTEN AND INK4A/ARF
Leukaemia